Geron (GERN) Total Current Liabilities (2010 - 2026)
Geron (GERN) posted Total Current Liabilities of $73.6 million for Q1 2026, down 34.04% sequentially from $111.5 million in Q4 2025, and up 16.71% YoY from $63.0 million in Q1 2025.
Geron (GERN) Total Current Liabilities (2010 - 2026) Analysis & Trends
Geron has reported Total Current Liabilities for 17 years, with the latest figure at $73.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 16.71% year-over-year to $73.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.6 million (up 16.71% YoY) and the FY2025 annual result came in at $111.5 million, up 26.32% from the prior year.
- Total Current Liabilities retreated to $73.6 million in Q1 2026 per GERN's latest filing, from $111.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $137.9 million in Q3 2024 and troughed at $43.9 million in Q1 2023.
- A 5-year average of $83.5 million and a median of $82.8 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 180.47% in 2024, then tumbled 48.82% in 2025.
- Over 5 years, Total Current Liabilities stood at $76.7 million in 2022, then surged by 40.91% to $108.1 million in 2023, then slipped by 18.3% to $88.3 million in 2024, then gained by 26.32% to $111.5 million in 2025, then sank by 34.04% to $73.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $73.6 million, $111.5 million, and $87.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Geron | 1.05 Mn | -299.80 Mn | - | 70.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.33 Mn |
| Mar 31, 2026 | 73.57 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 87.71 Mn |
| Jun 30, 2025 | 64.28 Mn |
| Mar 31, 2025 | 63.03 Mn |
| Dec 31, 2024 | 88.30 Mn |
| Sep 30, 2024 | 137.93 Mn |
| Jun 30, 2024 | 103.54 Mn |
| Mar 31, 2024 | 123.16 Mn |
| Dec 31, 2023 | 108.07 Mn |
| Sep 30, 2023 | 89.39 Mn |
| Jun 30, 2023 | 72.57 Mn |
| Mar 31, 2023 | 43.91 Mn |
| Dec 31, 2022 | 76.69 Mn |
| Sep 30, 2022 | 82.81 Mn |
| Jun 30, 2022 | 46.88 Mn |
| Mar 31, 2022 | 46.63 Mn |
| Dec 31, 2021 | 45.52 Mn |
| Sep 30, 2021 | 38.47 Mn |